ArticleBioorganic & medicinal chemistry letters2016
Three-dimensional QSAR analysis and design of new 1,2,4-oxadiazole antibacterials.
Article in Bioorganic & medicinal chemistry letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Targeting SleC and CspB in the Inhibition of Spore Germination inJournal of medicinal chemistry · 2025Article
- A newFuture microbiology · 2025Article
- Preparation and kinetic studies of a new antibacterial sodium alginate gelatin hydrogel composite.Scientific reports · 2024Article
- 1,3,4-Oxadiazole: An Emerging Scaffold to Inhibit the Thymidine Phosphorylase as an Anticancer Agent.Current medicinal chemistry · 2024Review
- ABDpred: Prediction of active antimicrobial compounds using supervised machine learning techniques.The Indian journal of medical research · 2024Article
- Design, green synthesis, and quorum sensing quenching potential of novel 2-oxo-pyridines containing a thiophene/furan scaffold and targeting aRSC advances · 2023Article
- Second-Generation Enamine-Type Schiff Bases as 2-Amino Acid-Derived Antifungals againstJournal of fungi (Basel, Switzerland) · 2023Article
- Unconventional Antibacterials and Adjuvants.Accounts of chemical research · 2021Article
- 3D-QSAR Studies of 1,2,4-Oxadiazole Derivatives as Sortase A Inhibitors.BioMed research international · 2021Article
- Isolation of endophytic bacteria from the leaves of Anredera cordifolia CIX1 for metabolites and their biological activities.BMC complementary medicine and therapies · 2020Article
- Novel 1,2,4-Oxadiazole Derivatives in Drug Discovery.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Exploration of the Structural Space in 4(3Journal of medicinal chemistry · 2020Article
- 1,2,4-Oxadiazole/2-Imidazoline Hybrids: Multi-target-directed Compounds for the Treatment of Infectious Diseases and Cancer.International journal of molecular sciences · 2019Article
- The oxadiazole antibacterials.Current opinion in microbiology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
The oxadiazole antibacterials, a class of newly discovered compounds that are active against Gram-positive bacteria, target bacterial cell-wall biosynthesis by inhibition of a family of essential enzymes, the penicillin-binding proteins. Ligand-based 3D-QSAR analyses by comparative molecular field analysis (CoMFA), comparative molecular shape indices analysis (CoMSIA) and Field-Based 3D-QSAR evaluated a series of 102 members of this class. This series included inactive compounds as well as compounds that were moderately to strongly antibacterial against Staphylococcus aureus. Multiple models were constructed using different types of energy minimization and charge calculations. CoMFA derived contour maps successfully defined favored and disfavored regions of the molecules in terms of steric and electrostatic properties for substitution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.